Sky Century Investment (SKYI) Change in Accured Expenses (2012 - 2026)
Sky Century Investment's (SKYI) quarterly Change in Accured Expenses came in at -$68265.0 in Q2 2026, down 210.38% year-on-year from $61847.0 in Q2 2025, and down 817.17% on a QoQ basis from -$7443.0 in Q1 2026.
Sky Century Investment (SKYI) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has 6 years of Change in Accured Expenses data on file, last reported at -$68265.0 in Q2 2026.
- On a quarterly basis, Change in Accured Expenses fell 210.38% year-over-year to -$68265.0 in Q2 2026; TTM through May 2026 was -$69415.0, a 164.97% decrease from a year earlier, with the FY2025 full-year figure at $59897.0, down 25.03% from the prior year.
- Change in Accured Expenses for Q2 2026 stood at -$68265.0, down from -$7443.0 in the prior quarter.
- Over the last five years, Change in Accured Expenses for SKYI reached as high as $61847.0 in Q2 2025 and fell as low as -$68265.0 in Q2 2026.
- Historically, Change in Accured Expenses has averaged $6500.2 across 3 years, with a median of $6173.0 in 2024.
- Across the five-year window, Change in Accured Expenses jumped 1961.57% in 2025 and plunged 210.38% in 2026, its largest moves.
- Year by year, Change in Accured Expenses stood at $21910.0 in 2024, then slumped by 57.34% to $9346.0 in 2025, then tumbled by 830.42% to -$68265.0 in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$68265.0 in Q2 2026, -$7443.0 in Q1 2026, and $9346.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.33 Bn | 87.46 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.12 Bn | 20.96 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | - |
| 10 | Sky Century Investment | 1.06 Mn | 1.06 Mn | 26,045.00 | -68,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -68,265.00 |
| May 31, 2026 | -68,265.00 |
| Feb 28, 2026 | -7,443.00 |
| Feb 28, 2026 | -7,443.00 |
| Nov 30, 2025 | 9,346.00 |
| Nov 30, 2025 | 9,346.00 |
| Aug 31, 2025 | -3,053.00 |
| Aug 31, 2025 | -3,053.00 |
| May 31, 2025 | 61,847.00 |
| May 31, 2025 | 61,847.00 |
| Feb 28, 2025 | -20,807.00 |
| Feb 28, 2025 | -20,807.00 |
| Nov 30, 2024 | 21,910.00 |
| Nov 30, 2024 | 21,910.00 |
| Aug 31, 2024 | 43,897.00 |
| Aug 31, 2024 | 43,897.00 |
| May 31, 2024 | 3,000.00 |
| May 31, 2024 | 3,000.00 |
| Feb 29, 2024 | 24,570.00 |
| Feb 29, 2024 | 24,570.00 |